Serological Biomarker Test (GastroPanel^®) in the Diagnosis of Functional Gastric Disorders,Helicobacter pyloriand Atrophic Gastritis in Patients Examined for Dyspeptic Symptoms

Abstract

Background/Aim: The GastroPanel ® test (Biohit Oyj) is interpreted by the GastroSoft ® application distinguishing eight biomarker profiles, of which five profiles have a morphological equivalent in the Updated Sydney System (USS) classification of gastritis, and 3 others specify functional disorders of the stomach: 1) high acid output, 2) low acid output, and 3) effects of proton pump inhibitor (PPI) medication. This study evaluated the prevalence of these biomarker profiles in dyspeptic patients. Patients and Methods: A cross-sectional study was designed to assess the point prevalence of these biomarker profiles in a random sample of 500 subjects derived from our archives of GastroPanel ® samples. Results: Reflux symptoms were reported by 35.2% and use of PPI medication by 36.8% of the study subjects. Biomarker profile 2 (high acid output) was the second most common GastroPanel ® profile in this cohort; 31.2%, second only (33.6%) to profile 1 (healthy stomach). Hp-infection was detected in 25.0% of the subjects. Profiles related to use of PPI (low acid output, PPI effect) were found in 7.4% of the cases. AG was uncommon, diagnosed in 14 patients only (2.8%). Conclusion: These data are derived from the population with the highest frequency of dyspepsia, and the results might have widespread implications in diagnostic and screening practices.

What Is New in Helicobacter pylori Diagnosis. An Overview

“…The GastroPanel ® , especially the new-generation test, which assesses H. pylori antibodies and pepsinogen (PG) I plus PG II and gastrin-17 in the plasma simultaneously, is able to predict H. pylori infection and the presence of atrophic gastritis with a likelihood of 94–95% [ 110 ]. The test was reported by several authors as the most comprehensive non-invasive diagnostic test, as it avoids false and negative results, with respect to conventional tests [ 57 , 110 , 111 , 112 , 113 ]. For example, in a study performed in Korea, a decreased PG I/II ratio was significantly associated with chronic atrophic gastritis and intestinal metaplasia ( p < 0.001) and, inversely, an increased ratio correlated with endoscopic findings, such as gastric and duodenal ulcer or nodular gastritis [ 111 ].…”

Efficacy of Bifidobacterium animalis subsp. lactis BL-99 in the treatment of functional dyspepsia: a randomized placebo-controlled clinical trial

“…Studies have confirmed that serum pepsinogen and gastrin levels in FD patients are different from those in healthy persons and are associated with various symptoms of FD 23 – 25 . For instance, Tahara et al 24 discovered that serum PGII levels were significantly elevated and the PGI/II ratio was significantly reduced in both H. pylori positive and negative FD patients compared to healthy controls.…”

Panel of serum biomarkers (GastroPanel) in diagnosis of atrophic gastritis and Helicobacter pylori infection: a protocol of systematic review and meta-analysis

“…New evidence has been published for the diagnostic performance indices of GP for both AG and HP infection. [29][30][31][32]…”

“…To our knowledge, there are no meta-analyses on diagnostic accuracy of GP for HP infection. New evidence has been published for the diagnostic performance indices of GP for both AG and HP infection 29–32…”